502 related articles for article (PubMed ID: 32266098)
21. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.
Huang P; Zhou X; Zheng M; Yu Y; Jin G; Zhang S
Front Immunol; 2023; 14():1263537. PubMed ID: 37767092
[TBL] [Abstract][Full Text] [Related]
22. A pyroptosis-associated gene risk model for predicting the prognosis of triple-negative breast cancer.
Qiu P; Guo Q; Pan K; Chen J; Lin J
Front Oncol; 2022; 12():890242. PubMed ID: 36276158
[TBL] [Abstract][Full Text] [Related]
23. Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.
Karn T; Jiang T; Hatzis C; Sänger N; El-Balat A; Rody A; Holtrich U; Becker S; Bianchini G; Pusztai L
JAMA Oncol; 2017 Dec; 3(12):1707-1711. PubMed ID: 28750120
[TBL] [Abstract][Full Text] [Related]
24. Tumor infiltrating CD8
Mella M; Kauppila JH; Karihtala P; Lehenkari P; Jukkola-Vuorinen A; Soini Y; Auvinen P; Vaarala MH; Ronkainen H; Kauppila S; Haapasaari KM; Vuopala KS; Selander KS
Oncoimmunology; 2015 Jun; 4(6):e1002726. PubMed ID: 26155410
[TBL] [Abstract][Full Text] [Related]
25. Clinical Relevance of Estrogen Reactivity in the Breast Cancer Microenvironment.
Takeshita T; Tokumaru Y; Oshi M; Wu R; Patel A; Tian W; Hatanaka Y; Hatanaka KC; Yan L; Takabe K
Front Oncol; 2022; 12():865024. PubMed ID: 35677163
[TBL] [Abstract][Full Text] [Related]
26. CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer.
Craven KE; Gökmen-Polar Y; Badve SS
Sci Rep; 2021 Feb; 11(1):4691. PubMed ID: 33633150
[TBL] [Abstract][Full Text] [Related]
27. Intratumoral lymphatic endothelial cell infiltration reflecting lymphangiogenesis is counterbalanced by immune responses and better cancer biology in the breast cancer tumor microenvironment.
Wu R; Sarkar J; Tokumaru Y; Takabe Y; Oshi M; Asaoka M; Yan L; Ishikawa T; Takabe K
Am J Cancer Res; 2022; 12(2):504-520. PubMed ID: 35261783
[TBL] [Abstract][Full Text] [Related]
28. Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer.
Liao G; Jiang Z; Yang Y; Zhang C; Jiang M; Zhu J; Xu L; Xie A; Yan M; Zhang Y; Xiao Y; Li X
BMC Med; 2021 Sep; 19(1):190. PubMed ID: 34465315
[TBL] [Abstract][Full Text] [Related]
29. Abundance of Regulatory T Cell (Treg) as a Predictive Biomarker for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Oshi M; Asaoka M; Tokumaru Y; Angarita FA; Yan L; Matsuyama R; Zsiros E; Ishikawa T; Endo I; Takabe K
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33086518
[TBL] [Abstract][Full Text] [Related]
30. High expression of STAT3 within the tumour-associated stroma predicts poor outcome in breast cancer patients.
Morrow E; Pennel K; Hatthakarnkul P; Leslie H; Mallon E; Andersen D; Jamieson N; McMillan D; Roseweir A; Edwards J
Cancer Med; 2023 Jun; 12(12):13225-13240. PubMed ID: 37199043
[TBL] [Abstract][Full Text] [Related]
31. Blocking Y-Box Binding Protein-1 through Simultaneous Targeting of PI3K and MAPK in Triple Negative Breast Cancers.
Tiwari A; Iida M; Kosnopfel C; Abbariki M; Menegakis A; Fehrenbacher B; Maier J; Schaller M; Brucker SY; Wheeler DL; Harari PM; Rothbauer U; Schittek B; Zips D; Toulany M
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 33003386
[TBL] [Abstract][Full Text] [Related]
32. The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC).
Narrandes S; Huang S; Murphy L; Xu W
BMC Cancer; 2018 Jan; 18(1):22. PubMed ID: 29301506
[TBL] [Abstract][Full Text] [Related]
33. Increased intratumor heterogeneity, angiogenesis and epithelial to mesenchymal transition pathways in metaplastic breast cancer.
Chouliaras K; Oshi M; Asaoka M; Tokumaru Y; Khoury T; Endo I; Ishikawa T; Takabe K
Am J Cancer Res; 2021; 11(9):4408-4420. PubMed ID: 34659895
[TBL] [Abstract][Full Text] [Related]
34. Integrated omics-based pathway analyses uncover CYP epoxygenase-associated networks as theranostic targets for metastatic triple negative breast cancer.
Apaya MK; Shiau JY; Liao GS; Liang YJ; Chen CW; Yang HC; Chu CH; Yu JC; Shyur LF
J Exp Clin Cancer Res; 2019 May; 38(1):187. PubMed ID: 31072371
[TBL] [Abstract][Full Text] [Related]
35. Enhanced immune response outperform aggressive cancer biology and is associated with better survival in triple-negative breast cancer.
Oshi M; Patel A; Wu R; Le L; Tokumaru Y; Yamada A; Yan L; Matsuyama R; Ishikawa T; Endo I; Takabe K
NPJ Breast Cancer; 2022 Aug; 8(1):92. PubMed ID: 35945417
[TBL] [Abstract][Full Text] [Related]
36. Intra-Tumoral Angiogenesis Is Associated with Inflammation, Immune Reaction and Metastatic Recurrence in Breast Cancer.
Oshi M; Newman S; Tokumaru Y; Yan L; Matsuyama R; Endo I; Nagahashi M; Takabe K
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32933189
[TBL] [Abstract][Full Text] [Related]
37. Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer.
Xiao Y; Ma D; Zhao S; Suo C; Shi J; Xue MZ; Ruan M; Wang H; Zhao J; Li Q; Wang P; Shi L; Yang WT; Huang W; Hu X; Yu KD; Huang S; Bertucci F; Jiang YZ; Shao ZM;
Clin Cancer Res; 2019 Aug; 25(16):5002-5014. PubMed ID: 30837276
[TBL] [Abstract][Full Text] [Related]
38. The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers.
Mokhlis HA; Bayraktar R; Kabil NN; Caner A; Kahraman N; Rodriguez-Aguayo C; Zambalde EP; Sheng J; Karagoz K; Kanlikilicer P; Abdel Aziz AAH; Abdelghany TM; Ashour AA; Wong S; Gatza ML; Calin GA; Lopez-Berestein G; Ozpolat B
Mol Ther Nucleic Acids; 2019 Mar; 14():301-317. PubMed ID: 30654191
[TBL] [Abstract][Full Text] [Related]
39. Long noncoding RNA Linc00339 promotes triple-negative breast cancer progression through miR-377-3p/HOXC6 signaling pathway.
Wang X; Chen T; Zhang Y; Zhang N; Li C; Li Y; Liu Y; Zhang H; Zhao W; Chen B; Wang L; Yang Q
J Cell Physiol; 2019 Aug; 234(8):13303-13317. PubMed ID: 30618083
[TBL] [Abstract][Full Text] [Related]
40. MAPK-RAP1A Signaling Enriched in Hepatocellular Carcinoma Is Associated With Favorable Tumor-Infiltrating Immune Cells and Clinical Prognosis.
Li H; Han G; Li X; Li B; Wu B; Jin H; Wu L; Wang W
Front Oncol; 2021; 11():649980. PubMed ID: 34178637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
